KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease (Accredited)


Mastocytosis, a rare clonal disorder of the mast cell, is frequently associated with somatic activating point mutations within KIT, most commonly D816V. 95% of Systemic Mastocytosis patients are positive for D816V when a sensitive assay is used. The detection of KIT D816V is not only important diagnostically but also for therapeutic decision making as the D816V mutation also confers resistance to some Tyrosine Kinase Inhibitors (TKI).


In this programme participants are provided with lyophilised cell-lines for KIT D816V mutation status analysis. The cell line has been kindly provided by The Mayo Clinic. Participants are asked to submit qualitative results, together with details of the methodology. Instructions for storage, reconstitution and use of the lyophilised samples are included with the samples. Three send-outs are issued per annum, with each send-out consisting of two samples.


Pre issue testing of samples for this programme is subcontracted, although the final decision about sample suitability lies with the EQA provider; no other activities in relation to this EQA programme are subcontracted.


To register for this programme, please click here.

Example KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease Report
202101 KIT Example Report.pdf
Adobe Acrobat document [1.5 MB]
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease Performance Monitoring System
KIT p.Asp816Val (D816V) Mutation Status [...]
Adobe Acrobat document [224.0 KB]
Print Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube


Last updated 20/05/2021 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.

Please click here for our privacy policy.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).